参议院报告显示,80%的美国非专利药物成分来自中国和印度,引发了安全和安保关切。 Senate report reveals 80% of U.S. generic drug ingredients come from China and India, sparking safety and security concerns.

参议院的一份报告警告说,美国非专利药物中80%的活性成分来自中国和印度,这引起了公共卫生和国家安全的担忧。 A Senate report warns that 80% of active ingredients in U.S. generic drugs come from China and India, raising public health and national security concerns. Rick Scott参议员强调国内生产急剧下降 — — 从2002年的83%下降到2024年的37% — — 并引用了2025年的一项研究,该研究显示,印度制造的非专利商品的不良事件比美国制造的版本要严重54%。 Senator Rick Scott highlighted a sharp decline in domestic production—from 83% in 2002 to 37% in 2024—and cited a 2025 study showing Indian-made generics had 54% more serious adverse events than U.S.-made versions. 报告呼吁进行改革,包括建立国内药品的联邦买主市场、供应链测绘、原产地标签和更有力的贸易措施,以减少对外国制造业的依赖,并确保药品的安全和供应。 The report calls for reforms including a federal buyer’s market for domestic drugs, supply chain mapping, origin labeling, and stronger trade measures to reduce reliance on foreign manufacturing and ensure medicine safety and availability.